Synthetic In Vitro Delivery Systems for Plasmid DNA in Eukaryotes
Success for gene therapy clinical protocols depends on the design of safe and efficient gene carriers. Nature had already designed efficient DNA or RNA delivery devices, namely virus particles. However, they have a propensity to trigger neutralizing and other immune responses. Also, the risk of insertional mutagenesis have limited their clinical use. Alternatively, safer approaches involving non-viral carriers have been and continue to be developed although they have not reached the transfection levels achieved by viruses. Those methods can be broadly classified into two categories: chemical and physical methods. In this review we present the most common and recent chemical non-viral methods to introduce, in vitro, pDNA into eukaryotic cells.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Review Article
Publication date: March 1, 2014
More about this publication?
- Journal of Nanopharmaceutics and Drug Delivery (JND) is an international peer- reviewed journal that covers all aspects of nanotechnology that applies to development, formulation and delivery of pharmaceuticals and diagnostic agents. This includes nanoscale pharmaceutics; tools to understand nanoscale pharmaceutical processes in drug discovery and development; design and development of nanoformulations and nanoscale drug delivery systems; regulatory aspects and policies related to nanopharmaceuticals. The journal has been developed to create a new forum for scientific publications at the interface of nanotechnology and pharmaceutical sciences. JND publishes original rapid communications, full research papers and timely state-of-the-art reviews (with author's photo and biography) encompassing fundamental and applied research in nanomaterials for drug delivery, nanopharmaceutics, nanomedicine, nanodiagnostics, nanobiotechnology and nanotoxicology of drug delivery carriers. Rapid communications on new findings with breakthrough results will be considered for accelerated publication.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Aims and Scope
- Ingenta Connect is not responsible for the content or availability of external websites